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1. Introduction
Clostridium difficile infection (CDI) is the most significant 
bacterial cause of hospital acquired (nosocomial) diarrhoea 
in adults (Bauer and Van Dissel, 2009). The severity of 
CDI ranges from mild, usually self-limiting, diarrhoea to 
fulminant colitis, toxic megacolon and death. C difficile 
colonises and can be isolated from 0-5% of healthy adults 
(Hautmann et al., 2011; Hell et al., 2012; Moudgal and 
Sobel 2012; Parkes et al., 2009). However, this can increase 
to 39% in hospitalised patients (Hickson, 2011; McFarland, 
2011) depending on treatment and local conditions, 
with individuals over the age of 65 being prime targets 
and age itself being a predisposing factor (referred to as 
‘inflammaging’ and ‘immunosenescence’; Islam et al., 2012). 
C. difficile is a gram-positive, anaerobic, spore forming 
bacillus first described in 1935 after isolation from the stool 
of a healthy newborn (Bacillus difficilis; Hall and O’Toole, 
1935). Normally, neonates develop a stable microbiota (even 
when colonised with C. difficile) without clinical problems, 
probably because they are short of (adequately expressed) 
toxin receptors in the still immature gut. Not until 1978 
was C. difficile recognised as an opportunistic pathogen for 
its antibiotic-associated diarrhoea and pseudomembranous 
colitis. CDI has rapidly increased since the 1990s with 
alarming rise since 2000 (1999-2007: 25% incidence-
increase per year in USA and 750% fatality rate increase 
in UK; Kelly, 2009) when the novel and fluoroquinolone 
resistant strain of PCR ribotype 027 spread and accounted 
for severe disease and over 40% of isolates (Islam et al., 
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Abstract
In the past two years an enormous amount of molecular, genetic, metabolomic and mechanistic data on the host-
bacterium interaction, a healthy gut microbiota and a possible role for probiotics in Clostridium difficile infection 
(CDI) has been accumulated. Also, new hypervirulent strains of C. difficile have emerged. Yet, clinical trials in CDI 
have been less promising than in antibiotic associated diarrhoea in general, with more meta-analysis than primary 
papers on CDI-clinical-trials. The fact that C. difficile is a spore former, producing at least three different toxins 
has not yet been incorporated in the rational design of probiotics for (recurrent) CDI. Here we postulate that the 
plethora of effects of C. difficile and the vast amount of data on the role of commensal gut residents and probiotics 
point towards a multistrain mixture of probiotics to reduce CDI, but also to limit (nosocomial) transmission and/or 
endogenous reinfection. On the basis of a retrospective chart review of a series of ten CDI patients where recurrence 
was expected, all patients on adjunctive probiotic therapy with multistrain cocktail (Ecologic®AAD/OMNiBiOTiC® 
10) showed complete clinical resolution. This result, and recent success in faecal transplants in CDI treatment, are 
supportive for the rational design of multistrain probiotics for CDI.
Keywords: Clostridium difficile, colonisation of GI tract, colonisation resistance, diarrhoea, intestinal mucosa
ht
tp
://
w
w
w
.w
ag
en
in
ge
na
ca
de
m
ic
.c
om
/d
oi
/p
df
/1
0.
39
20
/B
M
20
12
.0
04
9 
- M
on
da
y,
 A
pr
il 
30
, 2
01
8 
7:
49
:2
1 
A
M
 - 
IP
 A
dd
re
ss
:8
6.
90
.1
1.
15
9 
M. Hell et al.
40 Beneficial Microbes 4(1)
2012). Currently, CDI incidence rates are still high, but 
have dropped due to rapid diagnosis, improved infection 
control practice, root cause analysis, isolation of cases/
patients, and restricted use of antibiotics (stewardship). 
Since the problem with nosocomial infections also lies with 
spore-contaminated facilities and asymptomatic carriers 
(high IgG anti-toxin titers; Kyne et al., 2000), transmission 
reduction, in patients and health-care-workers alike, is an 
essential element in infection control.
2.  Clostridium difficile infection (mainly 
clinically manifested as diarrhoea)
General aspects
The normal microbiota inhibits (opportunistic) pathogen 
growth and toxin release. This function is reduced after 
gut-damage and demonstrably so in faecal samples of 
antibiotic-treated patients (Parkes et al., 2009). Causes 
for microbiota-damage are shown at level 2 in Figure 1. 
Risk factors for microbiota damage are for example age, 
proton pump inhibitors (PPI), tube feeding and parenteral 
nutrition (Hautmann et al., 2011). After initial disturbance 
of the resident microbiota other factors can exacerbate the 
condition by causing an unwanted bacterial overgrowth 
(Figure 1: 3) resulting in a mild (osmotic) diarrhoea 
that is usually self limiting (in over 75% of cases). When 
bacterial toxins are produced in sufficient amounts they 
will bind and structurally damage epithelial cells and/or 
the tight junctions, and the gut barrier is compromised 
(frequently also leading to bloody stools). This will then 
lead to an inflammatory cascade also involving the nervous 
system, which intensifies the diarrhoea. The reduction in 
fermentation also gives a reduction in the production of 
short chain fatty acids (SCFA) which normally provide 
energy and stimulation to colonocytes. Again, a large part of 
these violent episodes of diarrhoea is self limiting. When the 
immune system, diet and general condition of the patient are 
optimal, the resident microbiota will return and the cellular 
damage will be repaired by normal cellular regeneration 
(from crypt to apex of the villi 3-5 days). Prebiotic fibres 
like galacto- and fructo-oligosaccharides will accelerate 
restoration by preferentially creating a beneficial bifidogenic 
milieu whereas ‘simple’ sugars will enhance growth of 
opportunistic pathogens (Kelly, 2008). Similar beneficial 
effects as with prebiotics (specific vegetables in diet and/
or supplements like inulin) can be observed by oral intake 
of billons probiotic bacteria). Since the bacteria in the gut 
will always be counteracted by the (healthy) immune system 
(gut associated lymphoid tissue) only those bacteria that 
were considered ‘self ’ in early life will persist in view of the 
gut immune tolerance they enjoy. Hence, the same profile 
fingerprint of bacteria will emerge after a dysbiosis episode. 
In any case, the balance is usually restored after several 
weeks. Since probiotics do not permanently colonise the gut 
and are non-invasive, they will disappear (average half life 
5-7 days) when no longer ingested (Mercenier et al., 2000).
Clostridum difficile specific aspects
CDI has a number of specific properties making it the 
major nosocomial diarrhoea in adults. Firstly, CDI is 
particularly known for its specific risk factors age, use 
of antibiotics and hospitalisation (Hickson, 2011). When 
properly diagnosed, CDI is usually treated by withdrawal 
of the precipitating antibiotic, avoidance of anti-peristaltic 
agents and treatment with metronidazole or vancomycin 
for non-metronidazole-responders (Cohen et al., 2010) or 
severe cases. Still, up to a quarter of all patients will develop 
recurrent CDI (Hickson 2011), with those that experience 
such a relapse having a 50-60% risk of further recurrence 
(Bauer and Van Dissel, 2009). This is particularly so because 
of hypervirulent strains (like ribotypes 027, 078 and 106) 
with more severe disease, increased mortality, resistance 
to fluoroquinolones and higher relapse rates (Cartman 
et al., 2010). Additional mortality by these hypervirulent 
strains is calculated to be between 6-12% (Parkes et al., 
2009). Although some of these recurrent cases are due to 
exogenous reinfection by ongoing exposure to spores in 
the environment, most exhibit the same bacterial strain 
of the first episode. Evidently, neither the first antibiotic 
nor vancomycin restored the gut microbiota, nor did they 
reduce the exposure to spores in the environment, the co-
morbidity or other CDI specific host risk factors (Bauer 
and van Dissel, 2009). Fidaxomicin, a recently available 
anti-CDI drug has a very specific mode of action against C. 
difficile and does, therefore, less harm to the gut microbiota 
than any other comparable anti-C. difficile antibiotics 
(Tschudin-Sutter et al., 2012). Fidaxomicin is also described 
as preserving the intestinal microbiome during and after 
treatment of CDI and reducing both toxin reexpressions 
and recurrence of CDI (Louie et al., 2012).
CDI starts with ingested (or resident) spores germinating 
in the colon and the bacteria establishing/maintaining 
themselves through specific adhesion (Islam et al., 2012). 
CDI is toxin mediated (Figure 1: 4). Two large (approx. 
300 kDa) protein exotoxins, TcdA and TcdB, are produced, 
of which TcdB is clearly the main virulence factor as 
demonstrated by TcdA-veB+ve strains. The hypervirulent 
strain ribotype 027 produces an additional ‘binary’ toxin 
(CDT, an actin-specific ADP ribosyltransferase) whose 
role is not yet established, although it potentiates TcdA/B 
toxicity (Tschudin-Sutter et al., 2012). TcdA binds to the 
apical side of gut epithelial cells (to gp96, a C. difficile toxin 
A receptor) and causes cytoskeletal modification and tight 
junction disruption. This in turns facilitates binding of 
TcdB to the basal lamina leading to vascular permeability, 
release of neuropeptides (substance P, CGRP/calcitonin 
gene-related peptide and neurotensin), recruitment of white 
blood cells, pro-inflammatory cytokines (leukotrienes, 
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PGE2, TNFα, IL-1, IL-6) epithelial cell apoptosis, 
pseudomembrane (PM-colitis) formation, connective tissue 
degradation, fluid exudation/secretion and subsequently 
diarrhoea and frequently also bloody stools. In short, C 
difficile is pathogenetically unique in establishing a bona 
fide necro-inflammatory reaction activating mast cells, 
nerves, vascular endothelium and immune cells in addition 
to disruption of tight junctions (Hodges and Gill, 2010).
3.  Probiotics for prevention and treatment of 
diarrhoea
Maintenance of homeostasis and luminal effects
As shown in Figure 2, both the commensals in a normal 
microbiota as well as ingested probiotic products will assist 
in defending the gut against colonisation by exogenous 
microorganisms. This mechanism is called colonisation 
resistance (Wolvers et al., 2010). In a single cell to single 
1. Homeostasis of gut microbiota shown as 
    normal distribution of beneficial (green) and 
    unwanted (red) commensals and/or intruders 
2. Damage to microbiota through e.g.: 
– Antibiotics or chemotherapy 
– Diet or toxic compounds 
– Trauma or stress (inc. colonoscopy, surgery) 
– Anti-microbiota auto-immune response (e.g. IBD)  
3. Overgrowth of potentially pathogenic bacteria 
– Faulty diet or malnutrition 
– Deficient immune response 
– Fermentation ↓ → SCFA ↓ & carbohydrates ↑ 
   → osmotic pressure ↑ → colon absorbs less 
   → liquid stools
4. Damage to cells and barrier (can also be step 2)
– Toxins (red dots) give cytoskeletal modification 
– Disruption of tight junctions loss of barrier  
– Loss of absorptive microvilli (effacement)  
– Epithelial detachment (pseudomembranes)
5. Leaky gut barrier and infiltration 
– Cytotoxins bind to basolateral membrane 
leading to pro-inflammatory cytokines, vascular 
permeability, damage to connective tissue, 
infiltration of white blood cells, epithelial cell 
apoptosis. Release of neuropeptides stimulate 
enteric nerves leading to fluid loss: diarrhoea 
6. Beneficial bacteria return in numbers 
– Consumption of probiotic (purple)
– Dietary changes (e.g. prebiotics)
– Immune system (GALT) 
– Time (self limiting diarrhoea) 
7. As 1. Balance restored, bacterial profile 
(faecal fingerprint) as before due to memory 
immune response (probiotics don’t colonise & will disappear) 
Figure 1. Homeostasis, damage, barrier/function-loss and repair of the gut epithelium: role of microbiota and probiotics.
SCFA = short chain fatty acids; GALT = gut-associated lymphoid tissue.
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cell communication mechanism called quorum sensing 
some bacteria are able to down-regulate gene expression 
of pathogens, thereby decreasing virulence factors and/
or growth (Sherman et al., 2009). Furthermore, lactic acid 
bacteria produce a plethora of anti-microbial compounds 
including SCFAs, such as acetic, propionic, caproic 
and butyric acid, but also hydrogen peroxide, ethanol, 
acetaldehyde, diactyl, and carbon dioxide – all derived as 
either oxygen-catabolites or sugar-catabolites. Similarly, 
toxic compounds as fat and amino acid metabolites are 
produced, such as 3- and 4-hydroxy fatty acids, phenyllactic 
acid, aromatic and heterocyclic molecules. De novo protein 
synthesis by lactic acid bacteria results in antifungals, 
bacteriocins like reuterin and reutericyclin, and a host of low 
molecular mass peptides and cyclic peptides (see De Vuyst 
et al., 2009). Next to the bactericidal and bacteriostatic 
actions, these compounds can also downregulate expression 
of virulence factors, e.g. adherence molecules normally 
expressed by pathogens (Cadieux et al., 2009). Not only 
does the production of these compounds prevent dysbiosis 
in the gut, but this also explains why lactic acid bacteria 
have been used successfully for over three thousand years to 
conserve and sensorically improve food (milk, beer, sausage, 
sauerkraut, pickles, cheese, wine, etc.). Furthermore, SCFAs, 
like butyric acid, can also double in function as colonocyte 
fuel and can stimulate gut motility. Needless to say that 
efficient probiotics should share at least some of these, 
largely metabolomic, characteristics to be effective in vivo.
Mucosal effects
Antimicrobial factors are not only made by luminal lactic 
acid bacteria but also produced by the Paneth cells and 
secreted in the lumen at the mucosal surface, aiding in host 
Table 1. Contributions of electrogenic versus electroneutral components of ion absorption at the basis of Clostridium difficile 
diarrhoea mechanisms.a,b
Diarrhoea because of Mechanism through Molecules involved Relevant for C. difficile Role of probiotics c 
Increased secretion of 
electrolytes (CLCA) 1
Overproduction of cAMP 
gives activation of protein 
kinase A and opens CFTR 
and Cl- secretion2
CFTR and CLCA1 Increased Cl- secretion through 
neuropeptides (substance P, 
CGRP and neurotensin)
Bifidobacteria dose dependently 
inhibit (CFTR) Cl- secretion3 and 
promote intestinal homeostasis 
one step downstream epithelial 
Ca2+ mobilisation
Reduced sodium 
absorption
Luminal membrane Na+ and 
H+ exchange isoforms1,3
NHE3 (aka SLC9A3) TcdB inactivates Rho-kinase 
inhibitor altering activity and 
distribution of NHE34
Butyrate produced by probiotics 
increases NaCl absorption 
by NHE3 stimulation and 
transcription5
Reduced chloride 
absorption, 
increased HCO3 
secretion
Apical anion exchange 
mediating Cl- absorption 
(seen in congenital 
chloride diarrhoea)
DRA As for other infectious diarrhoea LPA or Lactobacillus acidophilus 
increase surface expression of 
DRA giving increased chloride 
absorption6,7
Reduced water 
absorption
ENS links directly with AQP8 AQP, ANG, OXT Hypothesis: lactic acid upregulates9 
AQP4, which facilitates oedema 
elimination in diseases causing 
vasogenic10 (vessel leak) 
oedema
Consumption of L acidophilus 
led to higher gene expression 
of water and ion homeostasis 
regulators11
Reduced sodium and 
glucose absorption
Inactivation of SGLT-1 SGLT-1 As for other infectious diarrhoea12 Microbiota influences expression 
of SGLT-113
Loss of barrier 
function, increased 
paracellular 
permeability
Altered tight junctions14,15 claudin-1, ZO-1, 
ZO-2, occludin
TcdA modifies cytoskeleton and 
disrupts tight junctions
Probiotics upregulate genes 
coding for de novo synthesis of 
claudin and occludin16,17
a Abbreviations used: ANG = angiogenin; AQP = aquaporins; CFTR = cystic fibrosis transmembrane conductance regulator; CLCA = chloride channel 
accessory; DRA = down regulated in adenoma; ENS = enteric nervous system; LPA = lysophosphatidic acid; NHE3 = Na/H exchanger3; OXT =oxytocin; 
SGLT-1 = sodium D-glucose cotransporter; TcdA = toxin A; ZO = zonula occludens (zonulin).
b Specific references given as superscript letters: 1Hodges and Gill, 2010; 2Ohland et al., 2012; 3Heuvelin et al., 2010; 4Hayashi et al., 2004; 5Malakooti et 
al., 2011; 6Borthakur et al., 2008; 7Singla et al., 2011; 8Ishihara et al., 2008; 9Morishima et al., 2008; 10Saadoun and Papadopoulos., 2010; 11Van Baarlen 
et al., 2011; 12Dean et al., 2006; 13Swartz et al., 2012; 14Ulluwishewa et al., 2011; 15Veshnyakova et al., 2012; 16Karczewski et al., 2010; 17Wells, 2011.
c Strains as examples, specifics in references/primary papers.
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defence by affecting numbers and/or composition of the 
colonising microbiota. As an integral part of the immediate 
response innate immune system, Paneth cells produce 
defensins and other antibiotic peptides and proteins. 
Because of their juxtaposition to epithelial progenitor (stem) 
cells at the base of the crypts of Lieberkűhn and very high 
local concentrations of defensins, they are probably involved 
in maintaining gut renewal. Reduced Paneth cell defensin 
expression can predispose for pathology, seen in necrotising 
enterocolitis and ileal Crohn’s disease (Salzman et al., 2007).
Probiotics can enhance release of defensins, e.g. as 
demonstrated in acute infectious enteritis (see Sherman 
et al., 2009). Trefoil-factors are anti-bacterial peptides that 
are also secreted by mucin-producing cells in response 
to various noxious stimuli (Sherman et al., 2009) or 
Exclusion by competition for: 
– Nutrients 
– Space in lumen & staeric hindrance ( → in figure) 
– Adherence to gut epithelium 
– Quorum sensing effector mechanisms 
Bacterial metabolic activity (green asterisks)  
– Acids ↓ pH & boost beneficial commensals
– Production of bactericides and bacteriostats
– Release of gut stimulators (e.g. butyrate) 
– Proteases for hydrolysis of toxins
Preservation of gut-barrier function 
– Upregulate synthesis tight junction proteins ( ↑↑ in figure)
– Decrease macromolecular permeability 
– Reduce bacterial translocation 
Influence water and ion channels 
– Probiotics inhibit secretion, stimulate absorption and 
upregulate gene expression and transcription of 
essential transport molecules 
Influence nervous system 
 – Enteroendocrine cells and subepithelial nerves
Modulation of signal transduction 
– Block activation & translocation of IFN-γ and
transcription factors like NF-κB to nucleus
– Idem for mitogen-activated protein kinases (MAPK)
– Enhance synthesis anti-inflammatory cytokines like  
   IL-10 and TGF-β
Stimulate innate immune system 
– Mucus production (Goblet cells), lysozyme 
– MAMPS microbe associated molecular patterns 
– Modulate TLR’s, RLR’s and NLR’s 
– Trigger Paneth cells to produce alpha-defensins
Initiate and boost adaptive immunity 
– Antigen uptake/presenting M & dendritic cells 
– From Peyer’s patches to mesenterical lymph nodes 
– Immune-cytokines (Th and Tregs)
– IgA, IgG and Ig antibodies
– Recirculating memory cells and HEV’s 
Paneth
cell
Dendritic
cell
Entero
endocrine
cell
Goblet
cell
Peyer’s
patch
M-cell
Figure 2. Microbiota, gut mechanisms and cells involved in prevention or reversal of diarrhoea.
IFN = interferon; NFκβ = nuclear factor kappa beta; IL = interleukin; TGF = transforming growth factor; MAMPS = microbe-associated 
molecular patterns; TRL = Toll-like receptor; RLR = retinoic acid inducible gene 1 like receptor; NRL = nucleotide oligomerisation 
domain like receptor; IG = immunoglobulin; HEV = high endothelial venules.ht
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probiotics (Van Huynegem et al., 2009). The enhanced 
mucus layer overlying the epithelial lining of the gut serves 
as an additional antibacterial shield, hampering binding 
of the pathogens (Sherman et al., 2009). Probiotics, such 
as Lactobacillus plantarum, can upregulate MUC2 and 
MUC3 genes, which code for mucus-protein production 
in humans. Mucus and trefoil factors work in concert with 
each other and many of the more than twelve hundred 
(!) antimicrobial peptides nature can call upon for host 
defence (Nakatsuji and Gallo, 2012). The gut wall exhibits 
a large degree of luminal chemo-sensitivity sensing a 
vast array of signals ranging from nutrients, chemicals, 
mechanical factors and microorganisms (Nguyen, 2012; 
Raybould, 2012). Entero-endocrine cells are specialised 
luminal sensors as are sub-epithelial nerve fibres that will 
respond to those compounds freely diffusing across the 
epithelium (e.g. SCFAs; Dockray, 2003).
Another direct relation between the nervous system and the 
gut is the presence, and exquisite sensitivity to probiotics, of 
opioid and cannabinoid receptors enabling manipulation of 
visceral perception (including pain; Rousseaux et al., 2007). 
As described in detail in Table 1, an intimate association 
between sensing, the nervous system, and ion and water 
homeostasis exist (Hodges and Gill, 2010). Sensing is also an 
integral part of the immune system via pattern recognition 
receptors (PRR) expressed on immune cells like dendritic 
cells and other tissues like the gut epithelium. PRRs 
recognise evolutionary conserved molecular structures 
known as microbe-associated molecular patterns or 
pathogen-associated molecular patterns and signal effector 
mechanisms in the innate immune system (Olive, 2012). 
PRRs can be divided in three families: Toll-like receptors, 
retinoic acid inducible gene 1 like receptors recognising 
viruses, and nucleotide oligomerisation domain like 
receptors. All are three families amenable to modulation 
by probiotics (Feleszko et al., 2006), excellently reviewed 
and described in their innate and adaptive immunity context 
by Wells (2011).
Based on these and other sensing mechanisms, relevant 
signal transduction pathways (see Figure 2 for NFkappaB 
and mitogen-activated protein kinase) can be switched 
on after recognition of pathogens leading to a cascade 
of events ending in the production of proinflammatory 
cytokines (as described above, cytokine storm) for defence 
or anti-inflammatory cytokines when tolerance is needed 
(Bron et al., 2011; Hodges and Gill., 2010; Sherman et al., 
2009; Van Baarlen et al., 2009). Selected probiotic strains 
and environmental markers of microbial exposure (Ege 
et al., 2011) can selectively modulate these pathways and 
enhance or suppress cytokine production switching the 
immune system between better defence (pathogens, tumour 
cells) and/or tolerance (to avoid allergy and auto-immunity; 
Guarner et al., 2006;).
M (microfold) cells, exclusively located over the Peyer’s 
patches, in the gut epithelium continuously sample the 
lumen for particles like microorganisms, transferring 
antigens to dendritic cells in the submucosa. Intraepithelial 
T and B lymphocytes produce cytokines (T) and 
immunoglobulins (B; antibodies) of IgA isotype mainly 
(Bron et al., 2012). Finally, the gut barrier, formed by only 
a single layer of epithelial cells, is critically dependent on 
tight junctions separating the gut lumen from the lamina 
propria. Bacteria from the microbiota and probiotics alike 
target the tight junction proteins and thereby modulate the 
barrier and thus permeability (Ulluwishewa et al., 2011).
Submucosal effects
The ‘business end’ of the gut immune system is mainly 
present in the lumen as sIgA immunoglobulin in the mucus 
layer on top of the epithelial cells and as intraepithelial 
lymphocytes. However, the actual initiation of the 
immune response takes place in the Peyers’s patches, large 
lymphocyte follicles in the submucosa. After the antigens 
are presented (by dendritic cells in villi or through M cells) 
and T and B cells are recruited the actual immune response 
is started in the draining mesenterical lymph nodes from 
where the activated T and B cells are transported back to the 
villi via the blood vessels (Brandtzaeg and Pabst, 2004; Bron 
et al., 2012). This seemingly elaborate mechanism ensures 
that the villi have more room for their primary function, 
uptake of nutrients and water, and that specific immune 
effector-cells can be initiated at one single site (after 
pathogen recognition) and then be evenly redistributed 
over the entire length of the gut, thereby providing uniform 
specific protection and memory. The entire process is 
critically controlled by dendritic cells and effector-cells 
are always under control of T regulator cells, ensuring 
not only a decent start of the specific response but also, 
and maybe more importantly, a timely end to the response 
(Wells, 2011) avoiding self-inflicted pathology (Chinen and 
Rudensky, 2012; Van Driel and Ang, 2008).
Clinical use of probiotics
With over 700 clinical trials in healthy volunteers and 
patients one might conclude that probiotics have come 
of age and their use is as evident as the mechanisms they 
modulate such as described above. Unfortunately, effects 
of probiotics are always dose and strain specific making 
comparison of clinical results with different preparations 
very difficult. In an effort to at least indicate in which areas 
probiotics can be recommended on scientific grounds, 
Floch et al. (2011) made an update of existing data. In 
their analysis they listed evidence as: ‘A = strong positive 
studies in literature’, ‘B = positive-controlled studies, 
but some negative studies not supporting the primary 
outcome’ and ‘C = some positive studies, but not enough 
for certainty’. They concluded that A claims can only be 
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given for infectious diarrhoea in children, antibiotic-
associated diarrhoea (AAD), pouchitis, ulcerative colitis 
(maintenance), immune response and atopic eczema. In 
most of these clinical indications a combination of probiotic 
strains instead of a monospecific single strain was used 
(Chapman et al., 2011).
Clinical use of probiotics in Clostridium difficile infection
In the studies by Floch et al. (2011), prevention of (recurrent) 
C. difficile associated diarrhoea was given a disappointing 
B/C marking and only one bacterial product with one 
strain (Lactobacillus rhamnosus GG; ATCC 53103) was 
included. Consequently, even with a substantial number of 
studies (Malaguarnera et al., 2012) and very positive meta-
analysis showing probiotics are associated with a reduction 
in AAD (Hempel et al., 2012; Videlock and Cremoni, 2012), a 
reliable probiotic formulation for CDI has still to be clinically 
(significance in intent-to-treat) proven. Still a positive 
attitude towards the future success of anti-CDI probiotics 
can be seen and specific recommendations for use are given 
(Hickson, 2011). Single strain versus multistrain preparations 
are still discussed controversially (Chapman et al., 2011). 
There is some evidence for single strain applications, such 
as non-toxigenic C. difficile strains, for treatment (Phase 2 
studies) based on the idea of a monoclonal pathogenesis 
of toxigenic C. difficile (Hell et al.2011). But a number of 
factors have to be taken into account when developing a 
new probiotic formulation in this field, these being: age of 
the host, optimal dose, stability, safety, mucosal adherence, 
gastric acid and bile resistance, matrix of delivery, specific 
strains, interaction within combination products and 
optimal duration of treatment (Verna and Lucak, 2010). 
The high efficiency of faecal microbiota transplantation is 
a fundamental fact that can be relied on in probiotic CDI 
treatment (Brandt., 2012; Tschuddin-Sutter et al., 2012). 
Based on this, a recent metanalysis by Johnston et al., 2012) 
and the fact that C. difficile has unique necro-inflammatory 
pathogenesis, as described in detail in Section 2, we postulate 
that only a multistrain cocktail (resembling a ‘healthy’ human 
microbiota) could come close to addressing all mechanistical 
needs (Figure 2 and Table 1) in the CDI setting.
4. Design and methods of a clinical study
For the reasons listed in the previous section a product 
(Ecologic®AAD, Winclove Bio Industries BV, Amsterdam, 
the Netherlands) was assembled consisting of equal ratios 
of the following 10 bacterial strains with a total dose of 5 
g/sachet and of 109 cfu/g: Bifidobacterium bifidum W23, 
Bifidobacterium lactis W18, Bifidobacterium longum W51, 
Enterococcus faecium W 54, Lactobacillus acidophilus W37 
and W55, Lactobacillus paracasei W20, L. plantarum W62, 
L. rhamnosus W71, Lactobacillus salivarius W24 and a 
mixture of 5% mineral elements, in Austria branded as 
OMNiBiOTiC® 10 AAD)).
Case definition
A patient was identified as a laboratory confirmed, 
symptomatic CDI patient who received adjunctive probiotic 
therapy at the time when oral metronidazol or vancomycin 
was initiated. Participants consumed sachets containing 5 g 
Ecologic®AAD twice daily. Patients were studied by queering 
surveillance data, consecutively followed by interviewing 
staff by phone. Retrospectively, medical records were 
reviewed to ascertain clinical signs of CDI, therapy, medical 
history and outcome.
Severe CDI was defined by clinical signs of severe colitis and 
laboratory findings confirming a severe course; recurrent 
CDI was defined as described by Bauer et al. (2009). 
The decision to initiate adjunctive probiotic therapy was 
made by the individual attending physician in cooperation 
with an infectious diseases consultant. On the basis of 
retrospective chart review all patients met the following 
criteria: diarrhoea, antibiotic treatment with metronidazole 
or vancomycin and multistrain probiotics.
Clinical setting and inclusion criteria
A 1,200 bed, tertiary care, university hospital (five different 
clinical departments) participated during the period from 
1 November 2010 to 31 July 2011. After laboratory proof of 
C. difficile (toxigenic culture), a standardised interview was 
carried out for each patient, asking for date and reason of 
admission, clinical symptoms, onset of clinical symptoms, 
underlying diseases, comorbities and antibiotic history. If 
the patient was selected for the study, patients’ records 
were searched for antibiotic history, additional medication 
like PPIs and cortison, fever, leukocyte counts, C-reactive 
protein (CRP), radiology and endoscopy results. A follow-
up was done after six month.
Treatment description and definition of resolution
To test whether the product was actually performing 
and no strain to strain inhibitory effects were introduced 
by combining so many strains, a pilot study including a 
series of ten elderly patients, complemented by a detailed 
chart review, was performed. Resolution was defined as 
no further laboratory signs of inflammation and/or fever, 
and reduction of stool frequency less than 3 times/24 h for 
at least 72 h according to Bauer et al. (2009).
All patients received oral vancomycin 125 mg qid for at least 
10 days, 8 patients received additionally oral metronidazole 
500 mg tid, 4 patients got a combination of oral vancomycin 
and iv treatment with metronidazole, and 9 were still under 
concomitant iv treatment with other antibiotics because 
of their underlying disease.
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A complementary epidemiological investigation was done 
outside the hospital CDI surveillance system for both the 
period of the investigated cases and for the time period 
2009-2011 (Table 2) to gain more background information 
of the local/hospital epidemiological situation.
5. Results of a clinical study
Table 2 clearly shows that the caseload of CDI is 
proportionally much higher in the group under 70 years 
of age, with 521 cases under 70 years of age versus 452 in 
the group over 70. In absolute numbers, the proportion 
of C. difficile fatal cases (causative and contributive cases) 
was 21 (<70) over 29 (>70), but in a relative way this was 
4% over 6.5% or a 63% increase in the >70 age bracket. No 
differences could be seen per 5 year age bracket >70. This 
clearly shows that the Salzburg cohort behaves as described 
in the literature (reviewed in Islam et al., 2012): relatively 
more CDI in older people and absolutely (and relatively) 
more deaths contributed to or caused by C. difficile in >70 
years. From this base line situation we selected the cases.
Patients characteristics, risk factors, and clinical 
presentation
The demographic characteristics, comorbidities, and 
clinical presentations of all patients are listed in Table 
3. The mean age of the patients was 82 years (range 72-
89); the majority were men (7 out of 10). All patients 
were hospitalised at the onset of CDI. Only one out of 
the 10 patients had no history of antimicrobials; 9 of 10 
received antimicrobial medication (range 1 to 6, mean 
3.7 different antibiotics) in the last three months before 
onset of CDI. The most frequently administered antibiotics 
were ciprofloxacin and amoxicillin+clavulanic acid (each 
5 out of 9 patients) and piperacillin+tazobactam (4 out of 
9 patients). 8 patients got PPIs and/or cortison before and 
during the CDI-therapy. 4 out of 10 patients had received 
different single-strain probiotics before. All but one patient 
suffered from severe underlying diseases like malignancies, 
renal failure or chronic vascular diseases. 6 of 10 patients 
showed fever (defined as body temperature ≥38 °C at the 
time the stool samples were taken). Mean leukocyte count 
was 13,500 (range 4,200 to 25,500) and mean CRP was 
13.7 g/dl (range 3 to 26.2 g/dl).
Laboratory and radiography results
In all patients, CDI had been confirmed by laboratory 
results (stool culture for C. difficile and toxin A- and 
B-positive ELISA test) before they were included in the 
survey. Radiography and endoscopy brought no further 
useful information: in 3 cases abdominal X-rays were 
done but without description of the colon; in one case an 
abdominal CT scan was performed, but, as the patient was 
already known for chronic radiogenic colitis, there was no 
valid information about CDI. In 2 out of 10 cases endoscopy 
was initiated. One showed no sign of enteritis, the other 
was aborted because of bleeding and stenosis.
Case reports
From the 10 patients who received adjunctive probiotic 
therapy 3 patients were selected to represent our case 
series population; these patients are discussed below. The 
demographic characteristics, comorbidities, and clinical 
presentations of all patients are listed in Tables 3 and 4. 
None of this three cases experienced a relapse for more 
than six months, however, as described below, one of them 
(patient 1) had already been treated with a multistrain 
probiotic for a short time period before and had a relapse 
two weeks later.
Patient 1 (Case 3 in Tables 3 and 4)
A 72 year-old male with tuberculosis, recurrent 
glomerulonephritis, and urinary tract infection (UTI) (due 
to extended spectrum β-lactamase producing Escherichia 
coli) who had been treated with hydrocortison and several 
antibiotics (ciprofloxacin, rifampicin, amoxicillin+clavulanic 
acid and sulfonamide+trimethoprim) for six months was 
admitted to our hospital with the second relapse of CDI. 
He tested positive for C. difficile (ribotype 413) in the stool 
specimen taken at admission. After an initial treatment 
with metronidazole he was treated with vancomycin 
and a multistrain probiotic. Three days later, the patient 
experienced full clinical resolution. Even after further 
treatment with ciprofloxacin and pivmecillinam for more 
than a month, no CDI-relapse occurred.
Table 2. Population characteristics of Clostridium difficile infection cases at University Hospital Salzburg from 2009 to 2011.
Age group Survived Died Causative Contributive Inconclusive % causative + contributive
<70 years 479 42 6 15 21 4.0
70-74 years 103 16 2 6 8 6.7
75-79 years 88 13 1 6 6 6.9
>80 years 209 23 3 11 9 6.0
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Table 3. Demographic characteristics, underlying disease, manifestation of Clostridium difficile infection (CDI) (primary episode, 
first or second relapse) and risk factors.
Ca
se
 ID
Ag
e
Se
x
Underlying disease Pr
im
ar
y C
DI
 ep
iso
de
Re
lap
se
 1
Re
lap
se
 2
Antimicrobials history Co
rti
co
st
er
oi
ds
/P
PI
1
1 88 m CDI x  None PPI
2 89 f uterus carcinoma x   Unknown antibiotic, Ciprofloxacin None
3 72 m glomerulonephritis x Ciprofloxacin, AmoxClav, Rifampicin, SulfTrim Cortison
4 85 f epilepsia x   Cefazolin, PipTaz PPI
5 85 m bladder carcinoma x Ciprofloxacin, PipTaz, Ceftriaxon, SulfTrim, 
Vancomycin, AmoxClav
PPI
6 80 m bronchitis, recurrent urinary tract infection x   Ciprofloxacin, Levofloxacin, SulfTrim PPI
7 76 m renal replacement therapy x   Ciprofloxacin, AmoxiClav, PipTaz Cortison, PPI
8 79 m endocarditis, CDI x  Clarithromycin, Moxifloxacin, Metronidazole Cortison, PPI
9 81 m peripheral arterial occlusive disease x   AmoxClav, Clarithromycin, Clindamycin, 
Ciprofloxacin, PipTaz
None
10 85 f sepsis, recurrent erysipelas, recurrent CDI x  AmoxClav, Meropenem, Metronidazole, 
Vancomycin, AmpSulbactam
PPI
1 PPI = proton pump inhibitors.
Table 4. Treatment, laboratory findings and outcomes of Clostridium difficile infection cases.1,2
Ca
se
 ID
St
oo
l  
C.
 d
iff
ici
le 
po
sit
ive
 
Re
pe
at
ed
 st
oo
l  
C.
 d
iff
ici
le 
po
sit
ive
PC
R 
rib
ot
yp
e
MT
Z
Pr
ob
io
tic
s h
ist
or
y
Fe
ve
r ≥
38
 °
C
Radiography3 Endoscopy Le
uc
oc
ite
 co
un
t/1
00
0
CR
P 
g/
dl
Cl
in
ica
l r
es
ol
ut
io
n
1 Y N 023 Y SSP Y N N 17.7 3 complete4
2 Y N 014 N N N Y, colon not described N 8.98 6.4 complete 
3 Y N 413 Y N Y Y, colon not described N 4.2 8 complete 
4 Y N 433 Y SSP Y N N 12.66 15.1 complete 
5 Y N 014 Y MSP Y Y, CT: known radiogenic 
colitis
Y, aborted, bleeding and 
stenosis
11.4 20.3 complete 
6 Y N nd Y SSP N Y, colon not described Y, no sign of enteritis 10.46 6.8 complete 
7 Y N nd Y N N N N 12.11 16.86 complete 
8 Y N 053 N N N N N 18.52 13.2 complete 
9 Y N nd Y SSP Y N N 25.48 26.2 complete 
10 Y nd 053 Y MSP Y N N 13.45 20.9 complete 
1 All patients received four times an oral dosage 125 mg vancomycin and twice daily a multistrain probiotic.
2 Abbreviations used: CRP = C-reactive protein; MSP = multistrain probiotic; MTZ = metronidazole; N = no; nd = not done; SSP = single strain probiotic; 
Y = yes.
3 Radiography with plain film, CT or sonography.
4 Patient died of pneumonia three months later.
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Patient 2 (Case 5 in Tables 3 and 4)
An 85 year-old male was admitted to our hospital with 
a known bladder carcinoma and recurrent CDI with 
diarrhoea. He had already been tested positive for C. difficile 
in stool specimens one month before, after he had received 
ceftriaxon, and tested positive again in the stool specimen 
taken at admission (ribotype 014). The first CDI episode 
was treated with vancomycin and a multistrain probiotic. 
The latter was prescribed for sixteen days, however, the 
patient was discharged from the hospital at day three. At 
readmission, he was treated first with metronidazole for 
five days; after consulting an infectious disease specialist, 
the therapy was switched to vancomycin, combined with 
a multistrain probiotic anew. Three days later, the patient 
experienced full clinical resolution.
Patient 3 (Case 8 in Tables 3 and 4)
A 79 year-old male who underwent transcutaneous 
aortic valve replacement developed endocarditis and was 
treated with clindamycin and ceftriaxon for one week, then 
followed by imipenem and moxifloxacin for 2 weeks. No 
diarrhoea was documented during this period nor stool 
samples were taken. One month later, after continously 
receiving moxifloxacin, he was readmitted with CDI, 
reporting diarrhoea at home for already two weeks. 
He tested positive for C. difficile (ribotype 053) in the 
stool specimen taken at admission and was treated with 
vancomycin and a multistrain probiotic. Five days later, the 
patient experienced full clinical resolution.
Treatment and outcomes
All patients under survey received 4× 125 mg oral 
vancomycin and 2× the multistrain probiotic. Five patients 
suffered from recurrent CDI. Complete resolution of clinical 
presentation occurred in 9 patients (90%), and one of the 
observed subjects died within a 3-months follow-up period 
from pneumonia, apparently without a connection to the 
CDI episodes. No adverse events were reported. A repeated 
stool testing was performed in 9 out of 10 patients and 
these proofed to be negative. Molecular characterisation of 
the strains was done in 70% (7 out of 10); PCR-ribotyping 
revealed thereby 5 different strains (2× 014, 2× 053 and 
one of each 023, 433, 413) (Table 4). No clustering or 
transmission was seen among the investigated patients.
Data from our surveillance system indicated 9 fatal courses 
directly related to CDI out of 151 cases (case-fatality ratio 
6%) during the observation period. 84 of the observed 
patients were males; the mean age was 67 (range 19-94). 
None of the fatal cases had a documented treatment with 
probiotics.
6. Discussion
Stool microbiota is best understood as a complex, living, 
interdependent ecosystem. During periods of health, 
bacterial gut residents suppress growth of C. difficile in 
the colon. Broad-spectrum antimicrobials have the potential 
to disrupt the balanced ecology of the stool microbiota, 
creating an opportunity for C. difficile spores to germinate 
resulting in overgrowth and attendant production of toxins, 
which are responsible for most of the clinical symptoms 
of CDI and (pseudomembraneous)-colitis. Antibiotics like 
clindamycin are known to impair colonisation resistance, 
however, second- and third-generation cephalosporins (for 
which all clinical isolates of C. difficile are resistant) and 
fluoroquinolones are frequently used in hospital infections/
patients and cause iatrogenic CDI (Kelly, 2009). Patients 
can keep shedding (bacteria, toxins and spores) for some 
weeks despite full clinical recovery. Those asymptomatic 
carriers emphasise the need for transmission reduction 
and universal infection control measures. Using gloves for 
avoiding direct skin contact and hand hygiene with plain 
soap and running water to remove spores followed by an 
alcoholic hand rub is preferred over alcohol-based hand 
rubs alone for symptomatic patients or patients with a 
recent known CDI-episode. To reduce the environmental 
burden, spores should be removed with sporicidal agents 
(chlorine) on surfaces adjacent to the patients, as well as 
for toilets and showers (Kelly 2009). Detergents based on 
peroxides or glutaraldehyde are also effective (Tschudin-
Sutter, 2012). The fundamental problem in CDI is not the 
presence of the pathogenic organism per se, but the absence 
of healthy microbiota to keep the growth of the pathogen 
suppressed. Accordingly, one would anticipate that the 
restoration of bacterial homeostasis in the colon could 
resolve diarrhoea states caused by uncontrolled growth 
of C. difficile.
C. difficile is a leading cause of AAD. The severity of 
CDI ranges from mild cases, which require little more 
than the discontinuation of antimicrobials to intractable 
diarrhoea, to relapsing infection and severe life-threatening 
illness. Mortality/fatality rates as high as 26% have been 
reported in old and very old patients, and patients with 
underlying disease like progressive solid tumours. Especially 
haematology-oncology patients, having systemic diseases 
and receiving high dose chemotherapy, are at risk for 
CDI (Hautmann et al., 2011). Both the recurrence and 
overgrowth after initial dysbiosis can be partly explained 
by spore forming ability, specific adhesions in the colon 
and hypervirulent strains via additional production of a 
binary toxin. The cost per case ranges from approx. 2,500 
USD (total cost estimate 3.5 billion) to 4,000 USD in the 
UK (Hickson, 2011), with health care system costs between 
5,000 (USA) and 8,000 (EU) USD per primary episode and 
almost 14,000 USD for a case of recurrent CDI (Hautmann 
et al., 2011) with a total burden worldwide in the tens of 
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billions. All available data show that CDI is much more 
difficult to prevent and cure than ordinary diarrhoea. In 
addition, the spore forming ability results in enormous 
recurrence rates.
Recent meta-analysis on CDI treatment successes (Johnston 
et al., 2012) in faecal transplantation in CDI therapy (Brandt, 
2012; Van Nood et al., 2013) and this case series shows that 
even in patients at high risk, with multiple severe underlying 
diseases, administration of multistrain probiotics might be 
beneficial by shortening the diseases course as well as by 
preventing further relapses in patients with recurrent CDI. 
Furthermore, this paper presents a theoretical and practical 
basis to initiate well-designed clinical trials (Morrow et al., 
2012) to evaluate multistrain probiotic treatment in CDI 
patient groups with different underlying diseases.
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